NTHI
HEALTHCARENeOnc Technologies Holdings Inc
AI Insight
What's Moving NTHI Today?
No stock-specific AI insight has been generated for NTHI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.60$12.99
$3.54
Fundamentals
Market Cap$95M
P/E Ratio—
EPS$-1.80
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume142K
Avg Volume (10D)—
Shares Outstanding25.9M
NTHI News
21 articles- NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet TransitionStocktwits·Jul 15, 2026
- NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data MilestoneStocktwits·Jun 23, 2026
- WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology StrategyYahoo Finance·Jun 22, 2026
- NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 DevelopmentStocktwits·Jun 16, 2026
- WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology UpdatesYahoo Finance·Jun 15, 2026
- The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the DecadeYahoo Finance·Jun 9, 2026
- NeOnc Technologies (NTHI) Could Be Targeting A Challenging Market With A Different StrategyYahoo Finance·May 31, 2026
- AI takes on brain cancer: how NeOnc targets the blood-brain barrierStock Titan·May 29, 2026
- NeOnc Provides Business Update and Reports Q1 2026 Financial ResultsYahoo Finance·May 18, 2026
- Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6247 Wall St·May 14, 2026
- NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data CatalystsYahoo Finance·May 5, 2026
- New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)Yahoo Finance·Apr 18, 2026
- NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial ResultsYahoo Finance·Apr 14, 2026
- NeOnc Provides Business Update and Reports Q4 2025 Financial ResultsYahoo Finance·Apr 1, 2026
- NeOnc Technologies Appoints David Choi as Chief Accounting OfficerYahoo Finance·Mar 13, 2026
- Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)Yahoo Finance·Mar 12, 2026
- NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ETYahoo Finance·Mar 4, 2026
- NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and ToxicityYahoo Finance·Feb 27, 2026
- New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin AmericaYahoo Finance·Feb 21, 2026
- New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)Yahoo Finance·Feb 14, 2026
- New to The Street(R) Airs Tonight on Bloomberg Television Across the U.S., MENA & Latin AmericaYahoo Finance·Feb 7, 2026
All 21 articles loaded
Price Data
Open$4.01
Previous Close$3.68
Day High$4.12
Day Low$3.52
52 Week High$12.99
52 Week Low$3.60
52-Week Range
$3.60$12.99
$3.54
Fundamentals
Market Cap$95M
P/E Ratio—
EPS$-1.80
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume142K
Avg Volume (10D)—
Shares Outstanding25.9M
About NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy and molecular medicine initiatives. The company boasts a compelling pipeline of innovative product candidates aimed at addressing critical unmet needs within oncology, which positions it as a potential leader in the evolution of cancer care. Backed by strategic partnerships within the biopharmaceutical sector, NeOnc has the capability to accelerate the commercialization of its groundbreaking therapies, presenting a compelling opportunity for institutional investors interested in the expanding cancer therapeutics market.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—